Literature DB >> 30817318

Interplay between the androgen receptor signaling axis and microRNAs in prostate cancer.

Rayzel C Fernandes1,2, Theresa E Hickey1, Wayne D Tilley1,2, Luke A Selth1,2.   

Abstract

The androgen receptor (AR) is a ligand-activated transcription factor that drives prostate cancer. Since therapies that target the AR are the mainstay treatment for men with metastatic disease, it is essential to understand the molecular mechanisms underlying oncogenic AR signaling in the prostate. miRNAs are small, non-coding regulators of gene expression that play a key role in prostate cancer and are increasingly recognized as targets or modulators of the AR signaling axis. In this review, we examine the regulation of AR signaling by miRNAs and vice versa and discuss how this interplay influences prostate cancer growth, metastasis and resistance to therapy. Finally, we explore the potential clinical applications of miRNAs implicated in the regulation of AR signaling in this prevalent hormone-driven disease.

Entities:  

Keywords:  androgen receptor; biomarkers; microRNA; prostate cancer; therapy

Year:  2019        PMID: 30817318     DOI: 10.1530/ERC-18-0571

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  10 in total

1.  New functions assigned to a microRNA with genetic links to prostate cancer risk.

Authors:  Akira Kurozumi; Shawn E Lupold
Journal:  Ann Transl Med       Date:  2019-09

Review 2.  Urinary microRNAs and Their Significance in Prostate Cancer Diagnosis: A 5-Year Update.

Authors:  Jaroslav Juracek; Marie Madrzyk; Michal Stanik; Ondrej Slaby
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 3.  MicroRNAs as Guardians of the Prostate: Those Who Stand before Cancer. What Do We Really Know about the Role of microRNAs in Prostate Biology?

Authors:  Thomas Andl; Kavya Ganapathy; Alexia Bossan; Ratna Chakrabarti
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

Review 4.  Targeting androgen receptor signaling with MicroRNAs and Curcumin: a promising therapeutic approach for Prostate Cancer Prevention and intervention.

Authors:  Zeeshan Javed; Khushbukhat Khan; Amna Rasheed; Haleema Sadia; Muhammad Naeem Shahwani; Asma Irshad; Shahid Raza; Bahare Salehi; Javad Sharifi-Rad; Hafiz A R Suleria; Natália Cruz-Martins; Cristina Quispe
Journal:  Cancer Cell Int       Date:  2021-01-26       Impact factor: 5.722

5.  MicroRNA-4287 is a novel tumor suppressor microRNA controlling epithelial-to mesenchymal transition in prostate cancer.

Authors:  Divya Bhagirath; Thao Ly Yang; Theresa Akoto; Nikhil Patel; Laura Z Tabatabai; Sharanjot Saini
Journal:  Oncotarget       Date:  2020-12-22

6.  MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.

Authors:  Divya Bhagirath; Michael Liston; Nikhil Patel; Theresa Akoto; Byron Lui; Thao Ly Yang; Dat My To; Shahana Majid; Rajvir Dahiya; Z Laura Tabatabai; Sharanjot Saini
Journal:  Oncogene       Date:  2020-10-09       Impact factor: 9.867

Review 7.  Coordinated AR and microRNA regulation in prostate cancer.

Authors:  Ieva Eringyte; Joanna N Zamarbide Losada; Sue M Powell; Charlotte L Bevan; Claire E Fletcher
Journal:  Asian J Urol       Date:  2020-06-19

Review 8.  microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation.

Authors:  Maureen Labbé; Christianne Hoey; Jessica Ray; Vincent Potiron; Stéphane Supiot; Stanley K Liu; Delphine Fradin
Journal:  Mol Cancer       Date:  2020-03-23       Impact factor: 27.401

Review 9.  Development and prevalence of castration-resistant prostate cancer subtypes.

Authors:  Jordan E Vellky; William A Ricke
Journal:  Neoplasia       Date:  2020-09-25       Impact factor: 5.715

10.  RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance.

Authors:  Jordan E Vellky; Sean T McSweeney; Emily A Ricke; William A Ricke
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-26       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.